Medindia

X

Wyeth Pharmaceuticals Announces Organizational Change

Friday, June 27, 2008 General News J E 4
Advertisement
COLLEGEVILLE, Pa., June 26 WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), announced today theappointment of Andreas Krebs, 50, to President - Europe/Middle East/Africa andCanada, effective immediately. In this new role, Mr. Krebs will report toJoseph M. Mahady, President - Wyeth Pharmaceuticals, and Senior VicePresident, Wyeth.

Mr. Krebs joined the Company in July 2003 as General Manager, WyethGermany, and since that time has worked to transform the German affiliate intoone of the fastest growing companies in the market. He serves on the Board ofthe VFA (Germany's trade organization for research companies) and is a memberof the Board of Trustees in the Max Planck Institute for Molecular Biomedicineand the Paul Ehrlich Society for Chemotherapy.

Prior to joining Wyeth, Mr. Krebs was with Bayer for approximately 20years, where he held a variety of pharmaceutical marketing and salesleadership positions in Europe, Latin America, Asia and Canada. He holds adegree in Commercial Management and Business Administration from the In-HouseAcademy of Woelm Pharma, Eschwege, Germany.

Wyeth is one of the world's largest research-driven pharmaceutical andhealth care products companies. It is a leader in the discovery, development,manufacturing and marketing of pharmaceuticals, vaccines, biotechnologyproducts, nutritionals and non-prescription medicines that improve the qualityof life for people worldwide. The Company's major divisions include WyethPharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

SOURCE Wyeth Pharmaceuticals
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Zysolin(TM) Improves Survival in Pivotal Animal St...
S
Novavax to Join Russell 3000 Index